Dianthus Therapeutics, Inc. /DE/ (DNTH) reporting calendar
Dianthus Therapeutics, Inc. /DE/ files periodic reports with the SEC as DNTH on Nasdaq. Atlas tracks 32 filed reports for this issuer, each linked to its original EDGAR accession.
- Next window
- 21 Jul 2026 – 24 Aug 2026
- Latest report
- 10-Q
- Period ended
- 31 Mar 2026
- Filed
- 5 May 2026
- Reports on record
- 32
How this window is derived. Derived from this issuer's own filing history: 9 periods at a median 91-day cadence, filed a median 38 days after period end. The SEC does not publish forward reporting dates and Atlas does not estimate one.
Open DNTH market profile
Latest filing on SEC EDGAR ↗
Pharmaceutical Preparations reporting datesAll Nasdaq reporting dates
Filed periodic reports
| Form | Period ended | Filed | Lag | SEC accession |
|---|---|---|---|---|
| 10-Q | 31 Mar 2026 | 5 May 2026 | 35 days | 0001690585-26-000022 |
| 10-K | 31 Dec 2025 | 9 Mar 2026 | 68 days | 0001690585-26-000006 |
| 10-Q | 30 Sep 2025 | 5 Nov 2025 | 36 days | 0001193125-25-266920 |
| 10-Q | 30 Jun 2025 | 7 Aug 2025 | 38 days | 0000950170-25-105030 |
| 10-Q | 31 Mar 2025 | 12 May 2025 | 42 days | 0000950170-25-069226 |
| 10-K | 31 Dec 2024 | 11 Mar 2025 | 70 days | 0000950170-25-037131 |
| 10-Q | 30 Sep 2024 | 7 Nov 2024 | 38 days | 0000950170-24-123285 |
| 10-Q | 30 Jun 2024 | 8 Aug 2024 | 39 days | 0000950170-24-093948 |
| 10-Q | 31 Mar 2024 | 9 May 2024 | 39 days | 0000950170-24-057022 |
| 10-K | 31 Dec 2023 | 21 Mar 2024 | 81 days | 0000950170-24-034681 |
| 10-Q | 30 Sep 2023 | 9 Nov 2023 | 40 days | 0000950170-23-062070 |
| 10-Q | 30 Jun 2023 | 3 Aug 2023 | 34 days | 0000950170-23-037605 |
| 10-Q | 31 Mar 2023 | 15 May 2023 | 45 days | 0000950170-23-022192 |
| 10-K | 31 Dec 2022 | 23 Mar 2023 | 82 days | 0000950170-23-009331 |
| 10-Q | 30 Sep 2022 | 3 Nov 2022 | 34 days | 0000950170-22-021603 |
| 10-Q | 30 Jun 2022 | 4 Aug 2022 | 35 days | 0001193125-22-211881 |
| 10-Q | 31 Mar 2022 | 16 May 2022 | 46 days | 0001193125-22-151014 |
| 10-K | 31 Dec 2021 | 8 Mar 2022 | 67 days | 0001193125-22-068759 |
| 10-Q | 30 Sep 2021 | 4 Nov 2021 | 35 days | 0001193125-21-319502 |
| 10-Q | 30 Jun 2021 | 5 Aug 2021 | 36 days | 0001193125-21-237060 |
| 10-Q | 31 Mar 2021 | 6 May 2021 | 36 days | 0001193125-21-152654 |
| 10-K | 31 Dec 2020 | 3 Mar 2021 | 62 days | 0001193125-21-066707 |
| 10-Q | 30 Sep 2020 | 5 Nov 2020 | 36 days | 0001193125-20-286283 |
| 10-Q | 30 Jun 2020 | 6 Aug 2020 | 37 days | 0001193125-20-211380 |
| 10-Q | 31 Mar 2020 | 7 May 2020 | 37 days | 0001193125-20-135615 |
| 10-K | 31 Dec 2019 | 3 Mar 2020 | 63 days | 0001193125-20-059835 |
| 10-Q | 30 Sep 2019 | 13 Nov 2019 | 44 days | 0001193125-19-290577 |
| 10-Q | 30 Jun 2019 | 8 Aug 2019 | 39 days | 0001193125-19-216106 |
| 10-Q | 31 Mar 2019 | 9 May 2019 | 39 days | 0001193125-19-142296 |
| 10-K | 31 Dec 2018 | 19 Mar 2019 | 78 days | 0001193125-19-078948 |
| 10-Q | 30 Sep 2018 | 8 Nov 2018 | 39 days | 0001193125-18-321954 |
| 10-Q | 30 Jun 2018 | 9 Aug 2018 | 40 days | 0001193125-18-244360 |
Source: SEC EDGAR company submissions for CIK 0001690585. Atlas publishes filed facts only. The SEC does not publish forward reporting dates, so no announced future date is claimed here.